GLPwatch
Cellular loci for cagrilintide action identified.
Nat Metab · 2026
Last updated 2026-07-22| Journal | Nat Metab, 2026 |
|---|---|
| Citations | 0 |
| Molecules | cagrilintide |
Full record and abstract on PubMed 42260118 ↗
Related research
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
- Development of Cagrilintide, a Long-Acting Amylin Analogue.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.